Abstract
The purpose of this study is to establish the prognosis of osteosarcoma patients based on the characteristics of immune-related gene pairs. We used the lasso Cox regression model to construct and verify the signature consisting of 14 immune-related gene pairs. This signature can accurately predict the overall survival of osteosarcoma patients and is an independent prognostic factor for osteosarcoma patients. For this we constructed a signature-based nomogram. The results of the nomogram show that our signature can bring clinical net benefits. We then assessed the abundance of infiltrating immune cells in each sample, and combine the results of the gene set enrichment analysis of a single sample to explore the differences in the immune microenvironment between IRPG signature groups. The result of gene set enrichment analysis shows the strong relationship between signature and immune system. Finally, we evaluated the relationship between signature and immunotherapy efficiency using algorithms such as TIMI and SubMap to explore patients who might benefit from immunotherapy. In conclusion, our signature can predict the overall survival rate of osteosarcoma patients and provide potential guidance for exploring patients who may benefit from immunotherapy.
Highlights
Osteosarcoma is a malignant bone tumor, which is mainly associated with children and adolescents [1]
We selected the The Cancer Genome Atlas (TCGA) cohort as the training set and identified a total of 32 immune-related gene pairs related to prognosis (P
We developed and verified an immune-related gene signature that can predict the overall survival of osteosarcoma patients
Summary
Osteosarcoma is a malignant bone tumor, which is mainly associated with children and adolescents [1]. Newly diagnosed osteosarcoma patients are mainly treated by chemotherapy and surgery, and the five-year survival rate can reach 60-70%. Some patients who are not sensitive to chemotherapy or have metastases only have a five-year survival rate of 20-30%, and new personalized treatment plans need to be developed to improve the prognosis of these patients [2, 3]. The most important guidelines for risk stratification and clinical decision making for patients with osteosarcoma are still clinical characteristics such as metastasis. Patients with the same clinical characteristics and the same treatment showed very different clinical results [4]. We have a need to consider the new prognostic factors to more accurately stratify patients to develop personalized treatment plans
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
